Study: Delaying evolution of drug resistance in malaria parasit... ( GAINESVILLE Fla. --- There's no magi...)

Study: Delaying evolution of drug resistance in malaria parasite possible

Date:9/4/2008

GAINESVILLE, Fla. --- There's no magic bullet for wiping out malaria, but a new study offers strong support for a method that effectively delays the evolution of drug resistance in malaria parasites, a University of Florida researcher says.

David Smith, associate director of disease ecology at UF's Emerging Pathogens Institute, said the study will guide scientists and policy makers in extending the longevity of current artemisinin-based malaria drugs combined with partner drugs. Smith is a co-author of a report on the study, scheduled to publish online this week in the Proceedings of the National Academy of Sciences and in print on Sept. 16.

Smith collaborated with lead author Maciej Boni of Resources for the Future and Princeton University, and Ramanan Laxminarayan, also with RFF, to create mathematical models assessing the strategic effectiveness and clinical outcomes of using one, two and three first-line drug therapies to treat malaria within a population over a 20-year period. Their results show that using two or three drugs simultaneously reduced the total clinical cases and number of failed treatments , and slowed the rate at which drug-resistant genes spread within the parasites that cause malaria: Plasmodium falciparum, P. vivax, P. malariae and P. ovale.

"The models indicate that we can slow the evolution of resistance to current artemisinin-based therapies if nations use them in combination with two or more partner drugs," Smith said. "Currently, most nations don't do this. They use one therapy at a time, wait for it to fail, and then switch to a different therapy."

Artemisinin-combined therapies, or ACTs, are currently not widely implemented due to operational challenges and expense, Smith said. But he said the study offers compelling evidence for global leaders to collaborate and overcome these issues.

"This is not to say that implementing multiple first-line therapies solves all of our malar
'/>"/>

Contact: DeLene Beeland
tdb@epi.ufl.edu
352-870-6856
University of Florida
Source:Eurekalert

0

GOOD

Page: 1 2 3
Related medicine news :

1. U. of Chicago study: More than 10 percent of older Americans suffer mistreatment
2. UNC study: chilling hardship rates among families raising disabled children
3. UNC study: Two-thirds of severe sports injuries to female students due to cheerleading
4. UNC study: shape, not just size, impacts effectiveness of emerging nanomedicine therapies
5. Study: verbal aggression may affect childrens behavior
6. UNC study: Common vaginal infection may increase risk of HIV infection
7. Brain cancer study: Magnitude of post-vaccine immune response linked to clinical outcomes
8. UNC study: Out-of-pocket health care costs for disabled children vary widely by state
9. Study: Global Business Performance Significantly Improved Through Project Management
10. Geisinger study: PTSD causes early death from heart disease
11. Study: 9/11 Dogs Suffered Few Health Effects

Post Your Comments:

(Date:11/9/2009)...l Nutrition announced today the acquisition of App...ed subsidiary of Natural Nutrition. Natural Nutri... the company will focus its efforts on the busines...oping mobile application market places throughout ...sed on multi platform apps designed to run on devi...

(Date:11/9/2009)...-Asia/ -- Simcere Pharmaceutical Group,(NYSE: SCR...eutical company,specializing in the development, m... proprietary pharmaceuticals in China, today annou...ense in China of Rosuvastatin from Tianjin,Tianda ...on of the,manufacturing license will be effected t...

(Date:11/9/2009)...eer development of scientists and science trainees...inical medicine, AAAS, Science Careers, and Scienc...e called CTSciNet, the Clinical and Translational ...B) November 6, 2009 -- Launched October 20 by Scie... CTSciNet is an online community for people purs...

(Date:11/9/2009)... now available in New York City by pain management...Y (PRWEB) November 9, 2009 -- Davis Bregman , a p...ouse calls to residents of Manhattan in New York C...l by calling the office at 212-918-1629 or sendin...e of being able to see the doctor in the less stre...

(Date:11/9/2009)...form Bill, The Affordable Health Care for American...aturday Night, and Is Expected to Be Signed into L...ith Absolute Confidence. ERISAclaim.com Announced ...cifically for the Compliance with the New Federal ... Hanover Park, IL (PRWEB) November 9, ...

Breaking Medicine News(10 mins):Health News:Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin 2 Health News:Social Network for Translational Scientists Launched 2 Health News:Social Network for Translational Scientists Launched 3 Health News:Social Network for Translational Scientists Launched 4 Health News:Davis Bregman MD Now Offering House Calls in Manhattan 2 Health News:The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim.com 2 Health News:The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim.com 3 Health News:The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim.com 4 Health News:The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim.com 5

[0] Natural Nutrition Acquires App Tech Global, Inc.[0] Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin [0] Social Network for Translational Scientists Launched [0] Davis Bregman MD Now Offering House Calls in Manhattan [0] The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim.com

...lecular Corporation, a,pioneer in the development ...lysis systems, announced today that Fran Tuttle ha.... Tuttle is president and chief executive,officer ...ard," said Xceed,s President and,CEO, David Deems....

...as released,today by the U.S. Department of Justic...m Ronald Tenpas, acting Assistant Attorney,General...n here at the,Department of Justice. Joining me to...nmental enforcement,settlement in the history of o...

...use study shows , TUESDAY, Oct. 9 (HealthDay News)...that may lead to a treatment for the hereditary, p...on,s disease (HD). , In mice, a molecule called C2... Disorders (MIND), Boston. Their study appears in ...

...finds , , TUESDAY, Oct. 9 (HealthDay News)...dren who,ve lost weight keep it off, new research ... effect of the maintenance programs wears off over...tudy. Clearly, maintenance treatment was better th...

...ose in commercial managed-care plans, study says ,...icaid enrollees receive lower quality health care ...tients in commercial health plans, a new study fou...nts. , "The policy message is that to the extent t...

...eveloped a potentially novel way to fight colorect...arrages of radiation inside cancer cells, unlike c...s and attack from the outside and cause unwanted s... cells, and whats left over is likely to be easily...

Xceed Molecular Names Fran Tuttle to Its Board of Trustees Transcript of Press Conference Announcing Settlement in United States Et Al vs. American Electric Power Molecule Promising Against Huntington's Disease Maintenance Treatment Helps Kids Keep Weight Off Medicaid Managed Care Seems to Fall Short Inside job: new radioactive agents for colon cancer work inside cells

(Date:11/6/2009)..., Nov. 6 NuVasive, Inc. ... on developing products for minimally disruptive s...the appointment of Michael J. Lambert as Executive...tive November 9, 2009. The Company also announced...,, "Michael will be an excellent complement to ...

(Date:11/6/2009)... Manitoba, Nov. 6 With his propose...has set his sights on cutting name-brand prescript... who fall into the "Part D" coverage gap, universa... about the potential cost-cutting and feel it,s a ... the most powerful lobbyists want a revised progra...

(Date:11/6/2009)...Nov. 6 Cyberonics, Inc. ...will report financial results for the second quart...g April 30, 2010 on Wednesday, November 18, 2009 a...nce call to discuss those results on Thursday, Nov... 2010 Second Quarter Results Conference Call Instr...

[0] NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates [0] Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole'[0] Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results

...tors to Better Target Patients for ALIMTA(R), (pem...ll Cell Lung Cancer, BARCELONA, Spain, Sept. 25 ...mall cell lung cancer (NSCLC) that,are classified ...ically,significant higher survival when treated in...d for injection) when compared to,histologically-s...

... (DSMB) Authorizes Enrollment of Cervical ...el, HOPKINTON, Mass., Sept. 24 Alseres,Pharmaceu...ndependent Data,Safety Monitoring Board (DSMB) has...ase I/IIa clinical trial in acute spinal cord inju... treated with a 9 mg dose of,Cethrin(R). This reco...

Other Medicine Technology:Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 2 Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 3 Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 4 Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 5 Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 6 Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 7 Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes 8 Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 2 Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 3 Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 4 Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial 5

Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial

...erence laboratory and a worldwide leader in innova...ers an extensive test menu of highly complex and u...logy. Owned by the University of Utah, ARUP Labora...on's university teaching hospitals and children's ...

Medicine Products:

Glucose, Body Fluid Glucagon Glomerular Basement Membrane Antibody, IgA (IFA)Gliadin Peptide Antibodies, IgA & IgG

Study: Delaying evolution of drug resistance in malaria parasit...( GAINESVILLE Fla. --- There's no magi...),Health